Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Actuate 1801: Elraglusib (9-ING-41) is an investigational study drug give alone or in combination with other chemotherapies, for the potenti… Ended

2024-518409-16-00 Refractory Hematologic Malignancies or Solid Tumors 7 2021-04-14
Breaking the big Five Barriers of Brain Metastasis: A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab… Ended

2024-512684-31-00 non-squamous nonsmall-cell lung cancer (NSCLC) metastat 4 2021-04-14
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
Study BT8009-100 in Patients with Nectin-4 Expressing Advanced Malignancies. Ended

2023-509781-37-00 Nectin-4 Expressing Advanced Malignancies. 7 2021-04-12
A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended

2023-509120-17-00 Myelofibrosis 5 2021-04-12
An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended

2023-507970-42-00 PSMA-positive metastatic hormone-sensitive prostate can 5 2021-03-31
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With locally advanced, Unresectable ESCC Ended

2023-506413-22-00 Locally Advanced Unresectable Esophageal Squamous Cell 5 2021-03-31
A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III r… Ended

2024-516554-22-00 Locally-advanced stage II-III rectal cancer 4 2021-03-29
A Study to Evaluate the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination w… Ended

2023-506899-27-00 Relapsed or refractory diffuse large B-cell lymphoma 5 2021-03-25
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto… Ended

2023-503916-33-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2021-03-24
IMMUNOGAST: An umbrella phase 2 trial to assess personalized targeted IMMUNOtherapy-based regimens in recurrent advanced/metastatic GASTric … Ended

2024-517816-31-00 For patients with advanced/metastatic gastric adenocarc 4 2021-03-19
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Ended

2024-512028-12-00 Advanced ROS1-positive non-small cell lung cancer 4 2021-03-19
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar… Ended

2024-516632-99-00 Advanced (stage III B-C-IV) ovarian, primary peritoneal 4 2021-03-17
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance… Ended

2022-502600-79-00 Endometrial cancer 4 2021-03-16
Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial) Ended

2023-504945-30-00 Primary or recurrent non-muscle invasive bladder cancer 5 2021-03-16
Pre- and post-menopausal women or men with advanced (loco-regionally recurrent not amenable to curative therapy or metastatic) HER2-positive… Ended

2023-508829-28-00 Pre- and post-menopausal women or men with advanced (lo 4 2021-03-15
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Solid tumors 4 2021-03-15
A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended

2022-502705-15-00 High-risk muscle-invasive bladder cancer 5 2021-03-08
A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat… Ended

2023-507695-52-00 Mantle cell lymphoma 5 2021-03-05
A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Fact… Ended

2022-502606-33-00 Patients with histologically or cytologically documente 5 2021-02-26
PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA). Ended

2024-516618-39-00 malignant pleural mesothelioma 4 2021-02-25
Iberdomide as maintenance therapy after autologous stem cell transplantation in newly diagnosed multiple myeloma patients Ended

2024-512354-21-00 Newly diagnosed multiple myeloma 4 2021-02-22
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in comb… Ended

2024-515988-55-00 Newly diagnosed multiple myeloma 4 2021-02-22
A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi… Ended

2023-509516-28-00 Stage II/Stage III rectal cancer or Stage II (high risk 4 2021-02-22